The drug pipeline is booming with new innovate specialty treatments for chronic conditions, but what does it mean for hospitals and health systems?
This comprehensive report breaks down the top trends, industry insights, and strategic impacts healthcare providers should consider moving forward.
Fill out the form to read our full 2026-2027 drug pipeline report, which includes a detailed analytical article plus an up-to-date chart of the recent and upcoming drug approvals/launches.
Specialty products dominate the 2026-2027 pipeline. These medications treat high-spend categories ranging from small-volume rare diseases to large-scale, common chronic conditions.
So far, this year is trending towards a record-number of novel drug approvals—and those treatment options are entering the market much sooner than they have before.
The question is no longer whether new treatment options will come to market soon or not. Given specialty’s dominance in the treatment landscape, access to limited distribution networks will be of utmost importance.
Read our full 2026-2027 drug pipeline report to learn all the strategic impacts and considerations you need to know moving forward.